| scholarly article | Q13442814 |
| P2093 | author name string | T. L. Lincoln | |
| J. B. Block | |||
| P. F. Morrison | |||
| W. H. Isacoff | |||
| J. Aroesty | |||
| K. L. Willis | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | levoleucovorin | Q192464 |
| pharmacokinetics | Q323936 | ||
| methotrexate | Q422232 | ||
| P304 | page(s) | 1665-1674 | |
| P577 | publication date | 1977-12-01 | |
| P1433 | published in | Cancer Treatment Reports | Q27710285 |
| P1476 | title | Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue | |
| P478 | volume | 61 |
| Q70760196 | Achievement of long duration methotrexate exposure with concurrent low dose thymidine protection: Influence on methotrexate pharmacokinetics |
| Q52677128 | Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. |
| Q71187004 | Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion |
| Q52682983 | Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses. |
| Q40184290 | Clinical pharmacokinetics of methotrexate in children |
| Q43246159 | Dosage and the pharmacokinetics of cytotoxic drugs |
| Q35718598 | Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. |
| Q70561515 | Effect of combination chemotherapy, duration of methotrexate administration, and patient's age on methotrexate pharmacokinetics |
| Q39852771 | High-dose Methotrexate Therapy-An Area of Uncertainty* |
| Q37634944 | Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches |
| Q72678279 | Impact of omeprazole on the plasma clearance of methotrexate |
| Q36478646 | Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy |
| Q52778977 | Mathematical modeling ?Guide to high-dose methotrexate infusion therapy |
| Q36363196 | Methotrexate-induced misincorporation of uracil into DNA. |
| Q40733350 | Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients |
| Q39768346 | Pharmacokinetics of anticancer drugs in children |
| Q69962086 | Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX |
| Q70868039 | Pharmacokinetics of methotrexate administered via the hepatic artery |
| Q52680287 | Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits. |
| Q69512898 | Renal excretion and pharmacokinetics of methotrexate and 7-hydroxy-methotrexate following a 24-h high dose infusion of methotrexate in children |
| Q70106598 | The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) |
| Q68362187 | The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits |
| Q40287530 | The practical benefits of pharmacokinetics in the use of antineoplastic agents |
Search more.